ECT-001 Clinical Trials
ECT-001-CB.001 Phase I/II Clinical Trial – for hematologic malignancies
- Approved by Health Canada in 2016
- Patients enrolled between Feb 2016 and Nov 2018
- Single expanded cord blood transplant in patients with hematologic malignancies
- Full trial details found here
- Full clinical trail results published in the The Lancet Haematology. 2020 Feb 1;7(2):e134-45. doi: 10.1016/S2352-3026(19)30202-9. PMID: 31704264
ECT-001-CB.002 Phase II Clinical Trial – for severe leukemia
- Approved by Health Canada in 2019
- Single expanded cord blood transplant in patients with severe leukemia/myelodysplasia
- Full details found here
ECT-001-CB.003 Phase II Clinical Trial – for multiple myeloma
- Approved by Health Canada in 2018
- Single expanded cord blood transplant in patients with multiple myeloma
- Full details found here
ECT-001-CB.004 Phase II Clinical Trial – for severe leukemia/myelodysplasia
- Approved by the FDA in 2019
- Single expanded cord blood transplant in patients with high risk leukemia/myelodysplasia
- Full details found here